HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − April 21, 2018
Data through : April 21, 2018
Table 4 − Progression to Step 2 by Site

	Overall	Baylor	Blantyre	Botha's Hill	DTTC−SU
Total Participants Enrolled[1]	119	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection[2]	78	0	0	0	0
Progressed to Step 2	73/78 (93.6%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Progression Status Pending	3/78 (3.8%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Did Not Progress to Step 2	2/78 (2.6%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product	1/78 (1.3%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Terminated from the study	1/78 (1.3%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/78 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (21APR2018,7:30)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − April 21, 2018
Data through : April 21, 2018
Table 4 − Progression to Step 2 by Site

	Emavundleni	Gaborone	Isipingo	Kisumu	Lilongwe
Total Participants Enrolled[1]	0	8	0	0	0
Participants who have been enrolled for 6 weeks or received injection[2]	0	5	0	0	0
Progressed to Step 2	0/0 (−%)	4/5 (80.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Progression Status Pending	0/0 (−%)	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Did Not Progress to Step 2	0/0 (−%)	1/5 (20.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product	0/0 (−%)	1/5 (20.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Terminated from the study	0/0 (−%)	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (−%)	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (21APR2018,7:30)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − April 21, 2018
Data through : April 21, 2018
Table 4 − Progression to Step 2 by Site

	MU−JHU	Parirenyatwa	Seke South	Soweto	Spilhaus
Total Participants Enrolled[1]	0	16	0	32	0
Participants who have been enrolled for 6 weeks or received injection[2]	0	7	0	26	0
Progressed to Step 2	0/0 (−%)	7/7 (100.0%)	0/0 (−%)	25/26 (96.2%)	0/0 (−%)
Progression Status Pending	0/0 (−%)	0/7 (0.0%)	0/0 (−%)	0/26 (0.0%)	0/0 (−%)
Did Not Progress to Step 2	0/0 (−%)	0/7 (0.0%)	0/0 (−%)	1/26 (3.8%)	0/0 (−%)
Permanently discontinued from the study product	0/0 (−%)	0/7 (0.0%)	0/0 (−%)	0/26 (0.0%)	0/0 (−%)
Terminated from the study	0/0 (−%)	0/7 (0.0%)	0/0 (−%)	1/26 (3.8%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (−%)	0/7 (0.0%)	0/0 (−%)	0/26 (0.0%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (21APR2018,7:30)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − April 21, 2018
Data through : April 21, 2018
Table 4 − Progression to Step 2 by Site

	St.Mary's Clinic	Swaziland	UVRI−IAVI	Verulam	Ward 21
Total Participants Enrolled[1]	18	0	0	0	30
Participants who have been enrolled for 6 weeks or received injection[2]	5	0	0	0	24
Progressed to Step 2	4/5 (80.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	23/24 (95.8%)
Progression Status Pending	1/5 (20.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	1/24 (4.2%)
Did Not Progress to Step 2	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/24 (0.0%)
Permanently discontinued from the study product	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/24 (0.0%)
Terminated from the study	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/24 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/5 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/24 (0.0%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (21APR2018,7:30)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − April 21, 2018
Data through : April 21, 2018
Table 4 − Progression to Step 2 by Site

	Zengeza
Total Participants Enrolled[1]	15
Participants who have been enrolled for 6 weeks or received injection[2]	11
Progressed to Step 2	10/11 (90.9%)
Progression Status Pending	1/11 (9.1%)
Did Not Progress to Step 2	0/11 (0.0%)
Permanently discontinued from the study product	0/11 (0.0%)
Terminated from the study	0/11 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/11 (0.0%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (21APR2018,7:30)